Envision Pharma Group announces the appointment of Bill Shirey to President of Life Science Commercialization
FAIRFIELD, Conn., July 30, 2024 (Newswire.com) – Envision Pharma Group (Envision) announced today the appointment of Bill Shirey as President of Life Science Commercialization. Overseeing the Two Labs and Riparian brands, Bill will focus on enhancing Envision’s commercialization and compliance
Asembia 2024 Unwrapped: Insights and Key Takeaways
This year’s Asembia Summit was not just an event; it was a powerhouse of innovation and strategic conversations that set new benchmarks for patient care within the pharmaceutical industry. Asembia served as the nexus for fostering connections and driving transformative
How Do You Know If Your Medical Device Needs State Licensing?
The medical device industry is growing, and we’re seeing the impact at Two Labs as more and more clients are asking us for support in launching their new medical device products. Additionally, we have observed a significant need for support
Sunshine transparency reporting for emerging pharma: Simplify, streamline, and secure
Pharmaceutical and medical device manufacturers launching their first product in the US face several complex challenges while preparing for the required collection and reporting of transfers of value provided to healthcare providers (HCPs) and healthcare organisations (HCOs). The many unique
Webinar Recap: Optimizing Patient Support: The Key Roles of Ongoing Training & Quality Monitoring
Two Labs Launches Aggregate Spend Offerings to Enhance Transparency and Compliance in the Pharma Industry
COLUMBUS, Ohio – Today, Two Labs, an Envision Pharma Company and industry leader in pharma services, officially launched its Sunshine Transparency and Aggregate Spend service. This service offering is designed to help emerging pharmaceutical manufacturers streamline their aggregate spend
Webinar Recap: The Future of Healing – Cell & Gene Therapies Entering 2024
As we close the year, we were happy to have so many people join us for our much-anticipated cell and gene pipeline webinar.
“Insights & Analysis 2024 Preview: Cell & Gene Therapies in the Drug Pipeline” was co-presented by Two
Barstools & Barcodes: 3 Types of Conversations I’m Having About the DSCSA Deadline
On this significant day, November 27, 2023, I find myself thinking about our slow and steady (emphasis on slow) march toward DSCSA compliance over the past 10 years. Introduced to serialization in 2015 as an LSS Black Belt at a
The 3 Most Important Elements for Any Product Launch
A lot of work goes into getting a new pharma product across the finish line, especially if you’re an emerging manufacturer launching your first product.
Every element of a launch strategy is important, but certain components outweigh others.
When you’re
FDA Special Designations and Programs for Pipeline Drugs: How They Impact Drug Development Deep Dive
Part 2 of 2: Special Designation Deep Dive
This is the second part of a two-part series from Two Labs Drug Pipeline Manager, Ryan Chandanais
In the first blog in this 2-part series, I provided an overview of FDA Special